These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12237249)

  • 21. [Effects of oxidized-low density lipoprotein on expression of urotensin II receptor GPR14 in rat aortic smooth muscle cells].
    Wang ZJ; Ding WH; Shi LB; Bu DF; Ren ZW; Tang CS
    Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):242-6. PubMed ID: 16677503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
    Holleran BJ; Beaulieu ME; Proulx CD; Lavigne P; Escher E; Leduc R
    Biochem J; 2007 Feb; 402(1):51-61. PubMed ID: 17064254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats.
    Gendron G; Simard B; Gobeil F; Sirois P; D'Orléans-Juste P; Regoli D
    Can J Physiol Pharmacol; 2004 Jan; 82(1):16-21. PubMed ID: 15052301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.
    Elshourbagy NA; Douglas SA; Shabon U; Harrison S; Duddy G; Sechler JL; Ao Z; Maleeff BE; Naselsky D; Disa J; Aiyar NV
    Br J Pharmacol; 2002 May; 136(1):9-22. PubMed ID: 11976263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.
    Boucard AA; Sauvé SS; Guillemette G; Escher E; Leduc R
    Biochem J; 2003 Mar; 370(Pt 3):829-38. PubMed ID: 12495432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
    Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
    J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.
    Douglas SA; Naselsky D; Ao Z; Disa J; Herold CL; Lynch F; Aiyar NV
    Br J Pharmacol; 2004 Jul; 142(6):921-32. PubMed ID: 15210573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urotensin-II receptor peptide agonists.
    Carotenuto A; Grieco P; Novellino E; Rovero P
    Med Res Rev; 2004 Sep; 24(5):577-88. PubMed ID: 15224381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
    Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
    J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro.
    Spinazzi R; Albertin G; Nico B; Guidolin D; Di Liddo R; Rossi GP; Ribatti D; Nussdorfer GG
    Int J Mol Med; 2006 Dec; 18(6):1107-12. PubMed ID: 17089015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urotensin II and atherosclerosis.
    Loirand G; Rolli-Derkinderen M; Pacaud P
    Peptides; 2008 May; 29(5):778-82. PubMed ID: 17933432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction.
    Giebing G; Tölle M; Jürgensen J; Eichhorst J; Furkert J; Beyermann M; Neuschäfer-Rube F; Rosenthal W; Zidek W; van der Giet M; Oksche A
    Circ Res; 2005 Sep; 97(7):707-15. PubMed ID: 16141412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urotensin II evokes neurotransmitter release from rat cerebrocortical slices.
    Ono T; Kawaguchi Y; Kudo M; Kushikata T; Hashiba E; Yoshida H; Kudo T; Furukawa K; Douglas SA; Guerrini R; Calo' G; Hirota K
    Neurosci Lett; 2008 Aug; 440(3):275-9. PubMed ID: 18572318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.
    Hirose T; Takahashi K; Mori N; Nakayama T; Kikuya M; Ohkubo T; Kohzuki M; Totsune K; Imai Y
    Peptides; 2009 Jun; 30(6):1124-9. PubMed ID: 19463745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function.
    Maguire JJ; Kuc RE; Kleinz MJ; Davenport AP
    Peptides; 2008 May; 29(5):735-42. PubMed ID: 17905478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography.
    Disa J; Floyd LE; Edwards RM; Douglas SA; Aiyar NV
    Peptides; 2006 Jun; 27(6):1532-7. PubMed ID: 16290260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insight into the role of urotensin II-related peptide tyrosine residue in UT activation.
    Billard E; Létourneau M; Hébert TE; Chatenet D
    Biochem Pharmacol; 2017 Nov; 144():100-107. PubMed ID: 28784291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).
    Camarda V; Spagnol M; Song W; Vergura R; Roth AL; Thompson JP; Rowbotham DJ; Guerrini R; Marzola E; Salvadori S; Cavanni P; Regoli D; Douglas SA; Lambert DG; Calò G
    Br J Pharmacol; 2006 Jan; 147(1):92-100. PubMed ID: 16273120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
    Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological properties and functional determinants of the urotensin II receptor.
    Proulx CD; Holleran BJ; Lavigne P; Escher E; Guillemette G; Leduc R
    Peptides; 2008 May; 29(5):691-9. PubMed ID: 18155322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.